-
Something wrong with this record ?
Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer
J. Grim, M. Hroch, H. Miloš, J. Chládek, C. Jaroslav, J. Petera, P. Jiří, J. Martínková, M. Jiřina,
Language English Country New Zealand
Document type Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2007-06-01 to 1 year ago
Health & Medicine (ProQuest)
from 2007-06-01 to 1 year ago
- MeSH
- Chemoradiotherapy MeSH
- Fluorouracil administration & dosage adverse effects pharmacokinetics MeSH
- Infusions, Intravenous MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Rectal Neoplasms drug therapy metabolism pathology radiotherapy MeSH
- Follow-Up Studies MeSH
- Neoadjuvant Therapy MeSH
- Prospective Studies MeSH
- Antimetabolites, Antineoplastic administration & dosage adverse effects pharmacokinetics MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects therapeutic use MeSH
- Aged MeSH
- Neoplasm Staging methods MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND AND PURPOSE: This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response (pCR; residual disease-free stage) and toxicities of grade ≤2, using individual dosing predicted according to the steady-state plasma concentration (C ss) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). PATIENTS AND METHODS: This open-label prospective study enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m(2)/24 h. In Group 1b (N = 7), the patients were treated with an escalated dose of 400-1,000 mg/m(2)/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU C ss 50-100 µg/L. Tolerability was tested according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Radiotherapy was delivered with 10-15 MV photon beams at 1.8 Gy/fraction up to 50.4 Gy in 28 daily fractions for 5 days a week. Surgery followed 4-6 weeks after the completion of CHRT and clinical restaging. The pCR and residual tumour stage were evaluated using preoperative tumour downstaging in magnetic resonance, postoperative histopathological staging and tumour regression rate (residual disease). RESULTS AND CONCLUSION: The cumulative AUC of 5-FU (total exposure to the drug) correlated with cumulative 5-FU dose (r = 0.61; p < 0.001) and residual disease (r s = -0.53; p < 0.005). A higher target pCR rate was reached in patients individually treated (Group 2) who finished the whole 5-week CHRT. The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010662
- 003
- CZ-PrNML
- 005
- 20171219080826.0
- 007
- ta
- 008
- 160408s2015 nz f 000 0|engg|
- 009
- AR
- 024 7_
- $a 10.1007/s40262-014-0216-4 $2 doi
- 024 7_
- $a 10.1007/s40262-014-0216-4 $2 doi
- 035 __
- $a (PubMed)25503423
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Grim, Jiří $u Department of Oncology and Radiotherapy, University Hospital, Sokolská Street, 500 05, Hradec Králové, Czech Republic, grimj@lfhk.cuni.cz.
- 245 10
- $a Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer / $c J. Grim, M. Hroch, H. Miloš, J. Chládek, C. Jaroslav, J. Petera, P. Jiří, J. Martínková, M. Jiřina,
- 520 9_
- $a BACKGROUND AND PURPOSE: This study estimated patients' early response following neoadjuvant chemoradiotherapy (CHRT) of locally advanced rectal cancer based on 5-fluorouracil (5-FU). The target was to achieve pathological complete response (pCR; residual disease-free stage) and toxicities of grade ≤2, using individual dosing predicted according to the steady-state plasma concentration (C ss) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL). PATIENTS AND METHODS: This open-label prospective study enrolled 33 adult patients treated with 5-FU administered as a continuous intravenous infusion over 4-5 weeks, as follows: in Group 1a (N = 6), the patients received a standard dose of 300 mg/m(2)/24 h. In Group 1b (N = 7), the patients were treated with an escalated dose of 400-1,000 mg/m(2)/24 h. In Group 2 (N = 20), the patients were given dosing kinetically guided in order to reach the target range of 5-FU C ss 50-100 µg/L. Tolerability was tested according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Radiotherapy was delivered with 10-15 MV photon beams at 1.8 Gy/fraction up to 50.4 Gy in 28 daily fractions for 5 days a week. Surgery followed 4-6 weeks after the completion of CHRT and clinical restaging. The pCR and residual tumour stage were evaluated using preoperative tumour downstaging in magnetic resonance, postoperative histopathological staging and tumour regression rate (residual disease). RESULTS AND CONCLUSION: The cumulative AUC of 5-FU (total exposure to the drug) correlated with cumulative 5-FU dose (r = 0.61; p < 0.001) and residual disease (r s = -0.53; p < 0.005). A higher target pCR rate was reached in patients individually treated (Group 2) who finished the whole 5-week CHRT. The individual daily dose needed to reach the target C ss should be >350 mg/m(2) (up to 600 mg/m(2)) provided that 5-FU metabolic ratio is within the range of 2.5-6 and the cumulative AUC5wks is within 50-100 mg·h/L.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protinádorové antimetabolity $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D000964
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
- 650 _2
- $a chemoradioterapie $7 D059248
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fluoruracil $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D005472
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a intravenózní infuze $7 D007262
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a staging nádorů $x metody $7 D009367
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a nádory rekta $x farmakoterapie $x metabolismus $x patologie $x radioterapie $7 D012004
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hroch, Miloš, $d 1976- $7 xx0076212
- 700 1_
- $a Chládek, Jaroslav
- 700 1_
- $a Petera, Jiří
- 700 1_
- $a Martínková, Jiřina
- 773 0_
- $w MED00001154 $t Clinical pharmacokinetics $x 0312-5963 $g Roč. 54, č. 5 (2015), s. 503-15
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25503423 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20171219081022 $b ABA008
- 999 __
- $a ok $b bmc $g 1114091 $s 935030
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 54 $c 5 $d 503-15 $i 0312-5963 $m Clinical pharmacokinetics $n Clin Pharmacokinet $x MED00001154
- LZP __
- $a Pubmed-20160408